- Home
- AIRT vs ATRA Comparison
AIRT vs ATRA Comparison
Compare AIRT & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRT
- ATRA
- Stock Information
- Founded
- AIRT 1980
- ATRA 2012
- Country
- AIRT United States
- ATRA United States
- Employees
- AIRT N/A
- ATRA N/A
- Industry
- AIRT Air Freight/Delivery Services
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AIRT Consumer Discretionary
- ATRA Health Care
- Exchange
- AIRT Nasdaq
- ATRA Nasdaq
- Market Cap
- AIRT 54.3M
- ATRA 65.1M
- IPO Year
- AIRT N/A
- ATRA 2014
- Fundamental
- Price
- AIRT $20.20
- ATRA $6.57
- Analyst Decision
- AIRT
- ATRA Buy
- Analyst Count
- AIRT 0
- ATRA 6
- Target Price
- AIRT N/A
- ATRA $25.70
- AVG Volume (30 Days)
- AIRT 14.1K
- ATRA 306.8K
- Earning Date
- AIRT 02-10-2025
- ATRA 11-12-2024
- Dividend Yield
- AIRT N/A
- ATRA N/A
- EPS Growth
- AIRT N/A
- ATRA N/A
- EPS
- AIRT N/A
- ATRA N/A
- Revenue
- AIRT $284,091,000.00
- ATRA $100,439,000.00
- Revenue This Year
- AIRT N/A
- ATRA $1,339.87
- Revenue Next Year
- AIRT N/A
- ATRA N/A
- P/E Ratio
- AIRT N/A
- ATRA N/A
- Revenue Growth
- AIRT N/A
- ATRA 2111.34
- 52 Week Low
- AIRT $14.02
- ATRA $6.50
- 52 Week High
- AIRT $30.60
- ATRA $39.50
- Technical
- Relative Strength Index (RSI)
- AIRT 51.54
- ATRA 32.06
- Support Level
- AIRT $18.85
- ATRA $6.55
- Resistance Level
- AIRT $20.51
- ATRA $17.83
- Average True Range (ATR)
- AIRT 0.71
- ATRA 2.21
- MACD
- AIRT -0.07
- ATRA -0.91
- Stochastic Oscillator
- AIRT 66.83
- ATRA 0.16
About AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).